SEARCH

SEARCH BY CITATION

References

  • 1
    Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-2050.
  • 2
    Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127. Hepatology 2012;56(Suppl):569A.
  • 3
    Medrano J, Barreiro P, Resino S, Tuma P, Rodriguez V, Vispo E, et al. Rate and timing of Hepatitis C Virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-Infected and HIV-uninfected patients. Clin Infect Dis 2009;49:1397-1401.
  • 4
    Lawitz E, Poordad F, Kowdley KV, Jensen D, Cohen, S. Siggelkow, K. et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naïve HCV IL28B-CC genotype-1-infected subjects. J Hepatol 2012;56(Suppl 2):S7.